Search research articles
Contact Us
Filters
Showing results (41-50 of 67) with videos related to
Page
of 7
Sort By:
Clinical & Experimental Metastasis
|
June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Targeted Oncology
|
August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
Matteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
European Urology Oncology
|
June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
Philipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Cancer Medicine
|
February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
Mimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII
|
June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 67) with videos related to
Sort By:
Page
of 7
Clinical & Experimental Metastasis
|
June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Targeted Oncology
|
August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
Matteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
European Urology Oncology
|
June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
Philipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Cancer Medicine
|
February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
Mimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII
|
June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Page
of 7